INTERVIEW: Is An Early M&A Exit In Store For Clinical-Stage Axonics?
This article was originally published in Clinica
Axonics Modulation Technologies may have barely initiated clinical trials of its implantable sacral neuromodulation (SNM) system for managing urinary and fecal dysfunction, but the company has already attracted attention from some of medtech’s big players seeking to buy into a segment of the neuromodulation market that may be worth more than $1bn a few years from now.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.